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Abstract 
Background: Diabetes accelerates memory dysfunction in a continuous, slowly pathological process. Studies sug-
gest that the time course of certain biomarkers can characterize the pathological course of the disease to provide 
information for early intervention. Thus, there is an urgent need for validated biomarkers to characterize the cogni-
tive impairment induced by DM. We aimed to detect changes in cerebrospinal fluid biomarkers such as amyloid β42, 
phosphorylated tau protein, interleukin 6, and acetylcholine in diabetic rats over time, and to analyse the relationship 
between diabetes and cognitive impairment.
Methods: Rats were injected once intraperitoneally with 1% of streptozotocin to establish a diabetic model. Index 
changes were investigated longitudinally and all were measured at the end of the experiment at day 75. Aβ42, P-tau, 
IL-6, and ACh levels in CSF, insulin levels in plasma, and Aβ42 levels in plasma and brain tissue were measured by 
ELISA.
Results: Compared with control, the diabetic model showed ACh in CSF to be decreased by day 15, continuing 
lower out to day 75. Aβ42 changes in brain and blood showed the same trends but exhibited minima at different 
time points: day 30 in CSF and day 15 in plasma. After the minimum, Aβ42 in cerebrospinal fluid rose and levelled off 
lower than in the control group, whereas Aβ42 in plasma rose and went above the controls at day 30, slowly trend-
ing upwards for the remainder of the experiment. P-tau protein in CSF in diabetic rats showed an increasing trend, 
becoming significantly different from the controls at day 60 and day 75. Aβ42 in CSF was strongly negatively corre-
lated with blood glucose at day 15 and was negatively correlated with insulin in serum, particularly at day 45.
Conclusion: Our longitudinal research model suggest that changes in the measured biomarkers appear before 
learning and memory impairments do. Aβ42 and ACh in the diabetes model group clearly changed from day 0 to day 
45, and then P-tau and IL-6 varied significantly from day 45 to day 75. The reduced ACh levels observed possibly cor-
related with the factors common to changes in Aβ42, P-tau, and IL-6.
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Background
In recent years, the incidence of diabetes mellitus (DM) 
has been rising at an alarming rate. It has been reported 
that in China in 2010, the number of DM patients reached 
114 million, accounting for 11.6% of China’s adult popu-
lation and about one-third of total cases worldwide [1]. 
In research from the Netherlands, an increased risk 
of dementia was observed in patients suffering from 
type 2 diabetes [2]. Many studies have demonstrated a 
sequence of changes in neuropsychological and neu-
rological behaviour in patients with diabetes [3, 4], and 
cognitive impairment with an increased risk of dementia 
in DM patients has become a serious social problem [5]. 
Increasing numbers of studies show that DM is an inde-
pendent risk factor for Alzheimer disease (AD), vascular 
dementia, and other diseases closely related to AD. The 
mechanism of vascular dementia involves impairment of 
the insulin signalling pathway, altered glucose metabo-
lism, metabolic changes such as amyloid β42 (Aβ42) 
imbalance, phosphorylation of tau protein (P-tau), and 
release of inflammatory cytokines (e.g. interleukin 6). 
These changes cause neuronal apoptosis, neuronal dam-
age (particularly in the hippocampus), structural and 
functional synaptic damage, and neurotransmitter under-
expression, collectively leading to cognitive impairment 
[6].
However, several questions remain concerning the cog-
nitive impairment induced by DM: (1) Is the pathogen-
esis of the impairment caused by a sequence of phases, 
e.g. insulin signalling pathway damage, then impaired 
glucose metabolism, then inflammation? To understand 
this process, it is urgent to track the changes over time, 
particularly in insulin, Aβ42, tau protein, inflammatory 
cytokines, and other biological markers, to investigate the 
significance for pathogenesis of the intrinsic links among 
these. (2) What is the time dependence of the mechanism 
of damage as revealed by biomarkers, and of the result-
ing learning and memory deficit? The latter question has 
motivated research into preventative drug intervention in 
the hope of revealing the best time course of pharmaco-
therapy. Such research also uncovered the prevalence of 
blindness in DM.
Considerable evidence shows that diabetes accelerates 
memory dysfunction in a continuous, slowly pathologi-
cal process. The incidence is difficult to assess, sepa-
rate pathological stages are difficult to delineate clearly, 
and the injury mechanisms predominating at different 
times during this process continue to require clarifica-
tion, all of which has hindered research and the formu-
lation of optimal drug intervention strategies. A recent 
study in the United States suggests that the time course 
of certain biomarkers can characterize the pathologi-
cal course of the disease to provide information for early 
intervention [7]. Thus, there is an urgent need for vali-
dated biomarkers to characterize the cognitive impair-
ment induced by DM. It may be possible to interfere 
with the trajectory of the targeted biological markers in 
different phases of pathogenesis, and thus to provide the 
starting point for intervention in the disease process to 
prevent further damage. Studies have shown that dur-
ing diabetes-induced cognitive impairment, metabolic 
and biochemical changes occur in the brain earlier than 
changes in function or structure. The metabolic changes 
comprise imbalances between amyloid β (Aβ) production 
and clearance, abnormal phosphorylation of tau protein, 
altered IL-6 levels (also associated with estimated life-
time cognitive decline [8]), lack of neurotransmitters, and 
structural and functional damage to neurons, ultimately 
leading to cognitive dysfunction. Both the learning and 
memory impairment, which influence each other, and 
the metabolic changes induced by DM causing damage 
to neurons (as evidenced by structural and functional 
studies), are progressive. In light of our previous results, 
we put forward the following hypothesis: ‘Changes in 
brain Aβ, P-tau protein, IL-6, and ACh are the first early 
events in the memory impairment process, and after a 
delay, which indicates the intervention time window, 
may cause the cognitive impairment observed in DM’. It 
is necessary to establish that the brain damage in DM is 
secondary to ensure that delaying or preventing the ear-
liest pathological and functional changes will be effec-
tive. However, continuous dynamic multi-marker locus 
studies on cognitive impairment in diabetes have not yet 
been reported. Therefore, this study aimed to chart the 
time course of the biomarker changes—the initial mem-
ory impairment events—during the latency period of 
DM-induced cognitive impairment. The diabetes model 
was the streptozotocin (STZ)-injected rat, the biomark-
ers chosen for study were the CSF levels of Aβ42, P-tau, 
IL-6, and ACh, and the behavioural assessment method 
for learning and memory ability was the eight-arm maze 
test. We also looked at blood chemistry to obtain a better 
view of the entire pathological process, thereby providing 
a better understand of the stages of cognitive impairment 
induced by DM and experimental evidence to guide drug 
intervention. The study will also provide further evidence 
bearing on whether DM causes cognitive impairment.
Methods
Experimental animals
Male Wistar rats, 8–10 weeks old, weighing 200 ± 20 g, 
were obtained from the Beijing Vital River Laboratory 
Animal Technology Co., license number SCXK (Beijing) 
2012-0001. The animal groups were housed separately in 
a 12-h alternating light–dark environment, with a tem-
perature of 18–21°C and relative humidity of 50  ±  5%. 
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The experimental protocol was approved by the Animal 
Ethics Committee of the Harbin University of Commerce 
and was carried out in accordance with the Guidance 
Suggestions for the Care and Use of Laboratory Ani-
mals, issued by the Ministry of Science and Technology 
of China [9].
Diabetes model
Before the experiment, the animals were fasted for 12  h 
with water freely available. STZ stock solution was freshly 
prepared by dissolving STZ in citrate–sodium citrate 
buffer on an ice bath with protection from light, to give a 
1% solution (pH 4.2–4.4). To establish the diabetes model, 
we administered an intraperitoneal injection of STZ 
stock solution at a dose of 55 mg/kg for the model group 
(n  =  50), completing the injection within 10  min. We 
injected citric acid–sodium citrate buffer at the same vol-
ume (5.5 mL/kg) for the control group (n = 12). Seventy-
two hours after injection, blood glucose was determined 
using a kit (Built Technology Co., Ltd., Nanjing, China), 
and animals with a fasting plasma glucose ≥16.7 mmol/L 
[10] were selected for inclusion in the experiment.
Cerebrospinal fluid dynamic acquisition
CSF was continuously collected via the cisterna magna 
using a slightly modified version of a published proce-
dure [11]. In a one-time procedure for a given animal, an 
intravenous infusion needle was slowly inserted to reach 
the cerebellar cistern, and the other end was connected 
to a 1-mL syringe, permitting slow collection of cerebro-
spinal fluid. After animal surgery, the wound was closed 
and the animals placed singly in cages for 5–7  days for 
wound healing. Once the diabetes model was established, 
CSF was collected every 15 days from each rat.
Determination of Aβ42, P‑tau, IL‑6, and ACh in CSF, 
and Aβ42 content in brain tissue by ELISA
The Aβ42, P-tau, IL-6, and ACh contents of CSF were 
determined using ELISA kits (Bluegene Biotech Co., 
Shanghai, China). The microplate absorbance was meas-
ured at 450  nm. Diabetic rat brain tissues were taken 
at d75 and the homogenate centrifuged (15,000  rpm, 
10 min, 4°C, Sigma 3K30). Aβ42 level in the supernatant 
was measured by ELISA. A kit based on the Bradford 
method (Nanjing Jiancheng Technology Co., Ltd., Nan-
jing, China) was used to measure tissue protein content. 
The Aβ42 content of brain tissue was expressed as pico-
grams per milligram of total protein.
Learning and memory ability of rats determined by the 
eight‑arm maze test
After the diabetic rat model had been established 
for 60  days, learning and memory were tested by the 
eight-arm radial maze using a video behavioural analy-
sis system provided by the Huaibei Zhenghua Biologi-
cal Equipment Co., Ltd. (ZH-3000 type, Anhui, China). 
After completion of adaptive training, diet was restricted 
to 85% of ad  libitum daily consumption by weight. The 
rats were placed in the central area of a maze with an 
opaque cover, and the arm doors were opened. Behaviour 
was recorded for 10  min. Rats entered each arm from 
the central area searching for food, and entering an arm 
was considered to have occurred when 70% of the body 
was inside the door to the arm. If the food had not been 
finished after 10 min, the test was terminated. Rats were 
tested once daily for 5  days. Working memory errors, 
reference memory errors, and total foraging time were 
recorded.
Plasma Aβ42 and indicators of glucose metabolism
Before plasma sampling, rats were fasted for 12  h with 
water available. Blood (0.5 mL) was then collected from 
the retinal venous plexus and centrifuged (5,000  rpm, 
10  min) to separate the plasma. Plasma glucose was 
determined by the glucose oxidase method using a 
kit (Nanjing Jiancheng Technology Co., Ltd., Nanjing, 
China). Plasma insulin and Aβ42 levels were measured 
by ELISA using a kit (Bluegene Biotech Co., Shanghai, 
China).
Statistical analysis
SPSS 21.0 for Windows was applied for statistical data 
processing, and results were expressed as means ± stand-
ard deviations. Groups were compared using the inde-
pendent-samples t test. The Pearson correlation test was 
used for evaluation of relationships between the various 
biomarkers (ACh, Aβ42, P-tau, IL-6, insulin, glucose, and 
other indicators). P < 0.05 was adopted as the significance 
level for both t- and Pearson tests.
Results
Weight and general characteristics observed in diabetic 
rats
Compared with the control group, rats in the experimen-
tal diabetic model group showed apathy; curled, loose 
stools; wet litter; a heavy smell of urine; and other phe-
nomena. Seventy-two hours after intraperitoneal injec-
tion of STZ, the rats exhibited overeating, over drinking, 
and polyuria, a syndrome consistent with the clinical 
symptoms of diabetes. As in human diabetes, weight loss 
was observed (Fig. 1).
Fasting plasma glucose and insulin levels in diabetic rats
Our study found that 43 of 50 rats in experimental dia-
betic model group had elevated blood glucose levels, 
defined as higher than 16.7  mmol/L, at 72  h (0 day); 
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these rats were incorporated into the experiment. In the 
remaining animals, four died and three showed blood 
glucose levels not significantly changed. Compared with 
the control group, glucose was significantly increased 
in the experimental diabetic model group at day 30, day 
60, and day 75 (P < 0.01). Insulin in plasma was elevated 
in diabetic rats at day 15, day 30, day 45, and day 60 
(P < 0.05 or 0.01); However, at day 75, plasma insulin in 
diabetic rats was reduced compared with that in the same 
group at day 45 (P < 0.05) (Fig. 2).
Dynamic changes in Aβ42, P‑tau, IL‑6, and ACh levels 
in CSF of diabetic rats
During the experiment, CSF was collected six times from 
diabetic rats over the period day 0 to day 75. Compared 
with the control group, Aβ42 was lower in the CSF of 
diabetic rats at day 15 and at day 30 (P  <  0.05 or 0.01, 
respectively); it was also lower at day 30 compared with 
previous levels in the same group at day 15 (P  <  0.01). 
Model levels were also higher at day 45, day 60, and day 
75 than in the same group at day 30 (P < 0.01) (Fig. 3a). 
Compared with the control group, P-tau levels in the CSF 
of the experimental diabetic model group were signifi-
cantly increased at day 60 and day 75 (P < 0.01) (Fig. 3b). 
IL-6 was also increased in the CSF of the model group at 
day 60 and day 75 (P < 0.01) (Fig. 3c). Compared with the 
control group, ACh in the CSF of the diabetic rat model 
was severely lowered at day 15 (P < 0.01), continuing so 
to day 75 (Fig. 3d).
Determination of Aβ42 content in the blood of diabetic 
rats
Compared with the control group, Aβ42 in the blood 
of the diabetic rats was significantly lower at day 15 
(P < 0.05) and significantly higher at day 45 and day 75 
(P < 0.05 and 0.01, respectively). The Aβ42 levels in the 
blood of diabetic rats at day 30, day 45, and day 75 were 
significantly increased compared with those in the same 
group at day 15 (P < 0.01). The Aβ42 levels in the blood 
of diabetic rats at day 75 were also significantly increased 
compared with those at day 30 (P < 0.05) (Fig. 4a).
Determination of Aβ42 content in the brain tissue 
of diabetic rats
Compared with the control group, Aβ42 content in the 
brain tissue of diabetic rats was found to be increased by 
day 75 (178.99 ± 44.47 pg/mg prot; P < 0.05) (Fig. 4b).
Correlation analysis of various biomarkers in diabetic rats
Pearson correlation analysis showed that changes in ACh 
levels showed a high negative correlation with Aβ42, 
P-tau, and IL-6 in the CSF of diabetic rats, r = −0.916 















Fig. 1 Dynamic changes in rat body weight. In this figure, model rats (streptozotocin-treated group, n = 15) are compared with control rats (con-
trol group, n = 12). Means ± standard deviations are shown. For intergroup comparisons: *P < 0.05, **P < 0.01.
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(P < 0.05). In addition, at day 0 of the diabetes model, the 
indicators were not correlated; at day 15 of the model, 
Aβ42 in CSF showed a strong negative correlation with 
blood glucose, r =  −0.865 (P  <  0.05). At day 45 of the 
model, Aβ42 in CSF was strongly negatively correlated 
with insulin, r = −0.760 (P < 0.05) and insulin resistance 
index, r = −0.946 (P < 0.05). At day 75, Aβ42 in the blood 
and brain in the experimental diabetic model group 
showed low correlation (Tables 1, 2).
Determination of learning and memory ability by the 
eight‑arm maze test in diabetic rats
Foraging time was significantly longer in diabetic rats 
compared with control (P < 0.05). The number of refer-
ence memory errors was also increased significantly in 
diabetic rats compared with control (P < 0.05), suggesting 
that learning and memory ability in the diabetic rats were 
damaged by day 71 (Table 3).
Discussion
With the rapid recent increase in the incidence of dia-
betes, cognitive impairment induced by diabetes has 
attracted wide attention [1]. Since 2006, when Mijnhout 
[12] proposed a ‘diabetes-related cognitive impairment’, 
several studies have shown that diabetic patients and 
animal models exhibit cognitive dysfunction. Takeda’s 
research deepened understanding of the mechanistic 
links between the two types of disease [13]. Recent stud-
ies have shown unimpaired cognition in the AD process 
at the time when Aβ deposition occurs, and only after a 
delay are neurological dysfunction and degeneration seen 
[14]. We therefore have reason to believe that the brain 
levels of Aβ, P-tau protein, IL-6, and ACh mark early 
events in memory impairment.
From previous literature, it appears that there is no 
standard cognitive dysfunction induced by diabetic ani-
mal models; usually a DM model was established using 
a drug, and with extension of modelling time, cognitive 
function was observed to decline. The present study uses 
a single intraperitoneal injection of STZ to establish the 
model and tests were conducted over 75  days. During 
the experiment, the blood glucose in the experimental 
diabetic model group was stable at above 16.7  mmol/L, 
showing good model stability.
In this study, the various biomarker changes were fol-
lowed by collecting CSF from the rats, methods for which 
are broadly divided into two categories: the lateral ven-
tricle puncture, involving drilling a hole in the animal’s 
skull and inserting a drainage tube for collecting cerebro-
spinal fluid [15], and the extraction of CSF via a needle 
puncture into the cisterna magna [11]. Our experiment 
used a method based on a previous publication describ-
ing a one-time technique for collection through an intra-
venous infusion needle. We slightly modified this to a 
technique for multi-time-point collection from a sin-
gle animal. This enabled us to collect CSF from diabetic 
rats longitudinally over 0–75  days. This allowed us to 
avoid the need to sacrifice animals at each time point, 
thereby reducing the standard deviation of the data. As a 
result, dynamic biomarker changes were observed when 
DM caused major cognitive damage. Aβ42 and ACh in 
brain were the first to change significantly; P-tau and 
nilusnIbGPFa
































Fig. 2 Dynamic changes in a fasting plasma glucose and b plasma insulin. In these figures, model rats (streptozotocin-treated group, n = 15) are 
compared with control rats (control group, n = 12). Mean ± standard deviation is shown. For intergroup comparisons: *P < 0.05, **P < 0.01; compar-
isons within diabetic group between time points: #P < 0.05.
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IL-6 protein concentrations changed later and in a more 
gradual, progressive manner. Currently, there are reports 
of longitudinal clinical studies of biomarkers of cogni-
tive impairment; however, previous studies tended to 
explore more than a single pathology, rarely also discuss-
ing two or more dynamic changes in biomarkers or the 
long-term pathological evolution (e.g., over 2 months). In 
the present study, we collected cerebrospinal fluid from 
the cisterna magna five or six times per animal at several 
time points. The amount of CSF that could be collected 
per animal per time point was limiting in this experiment 
because of practical issues with diabetic rats; therefore, 
not all the indicators were measured at some time points. 
However, from related references and pilot experiments, 
we knew that diabetic rats have a cognitive impairment 
detectable from day 60 to day 70, and therefore, we knew 
the appropriate time to terminate the experiment and 
collect larger, adequate samples from all the animals. 
Before and after data were therefore available for all bio-
markers. Because of the abovementioned limitation, our 
laboratory intends to perform studies using non-invasive 
CSF collection methods, seeking methods by which it 
will be practical to collect cerebrospinal fluid at shorter 
time intervals, allowing better data to be obtained in 
future experiments.
The prevailing view is that diabetes is closely related to 
brain aging and dementia. Dementia is thought to result 
from an imbalance between Aβ production and clear-
ance, leading to loss of neurotransmitter expression and 
damaged synaptic function [16, 17]. This study found 
at day 15 a strong negative correlation of CSF levels of 
Aβ42 with blood glucose. Accordingly, we have reason 
to believe that, with the establishment of the diabetes 
model at day 0–day 15, elevated blood glucose can cause 
a  A uat-Pb24
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Fig. 3 Dynamic changes in CSF levels of a Aβ42, b P-tau, c IL-6, and dACh of cognitive impairment. In these figures, model rats (streptozotocin-
treated group, n = 15) are compared with control rats (control group, n = 12). Means ± standard deviations are shown. For intergroup compari-
sons: *P < 0.05, **P < 0.01.
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a severe precipitation phenomenon in Aβ42 in vivo, Aβ42 
in CSF showing a decline in the early stages of diabetes. 
It is known that Aβ42 levels in CSF inversely reflect the 
brain content of the fibrous, insoluble form of Aβ, which 
is the core component of senile plaques and is impor-
tant in their formation. Its precipitation occurs early in 
AD [18, 19]. In our model, the interval 15–30 days, when 
changes in blood glucose had stabilized, was instructive. 
Changes in Aβ42 levels in CSF bottomed later than did 
those in the blood, and we therefore speculate that at this 
time Aβ deposition may begin to appear in the brain. At 
day 30, Aβ42 in CSF hits ‘rock bottom’ due to the double 
impact of deposition and glycosylation.
It has been reported that hyperinsulinaemia in patients 
with chronic insulin resistance carries a significantly 
increased risk of cognitive dysfunction or dementia [20]. 
Watson et  al. found that in healthy older people who 
inject insulin, both insulin level and Aβ42 level could 
be increased in CSF [21]. In the present study, with syn-
chronous dynamic monitoring of plasma insulin levels 
in diabetic rats, we found that when the model plasma 
insulin levels were increased vs. controls (day 30–day 
45), a peripheral insulin resistance phenomenon being 
dominant, the plasma Aβ42 level was also significantly 
increased vs. controls, presumably due to Aβ42 degra-
dation and insulin degradation competing for the same 
substrate—insulin-degrading enzyme [22, 23]. In the dia-
betes model, day 45–day 75 is a period of falling plasma 
insulin levels, which may be associated with a negative 
feedback mechanism that reduces insulin levels by up-
regulating expression of insulin-degrading enzyme, accel-
erating Aβ42 degradation as well. However, the enzyme 
was again inhibited, leading to elevated blood levels of 
Aβ42. At the same time, correlation analysis at diabetic 
model day 45 showed Aβ42 in CSF to be negatively corre-
lated with plasma insulin and insulin resistance index. By 
observing changes over time, it can be seen that day 45 is 
the watershed of insulin level change, marking the begin-
ning of a decrease in insulin levels. At this time point, 
cerebrospinal fluid Aβ42 levels began to rise, the opposite 
trend, showing a negative correlation.
It is known that P-tau concentration reflects the level 
of neurofibrillary tangles in the brain. This study found 
that changes in P-tau in the CSF of rats in our diabetic 
model group occurred later than the changes in Aβ42; a 
significant increase in P-tau in CSF was observed only at 
day 60 and day 75. Studies have shown that after a fall in 
peripheral insulin levels, the insulin signalling pathway is 
down-regulated, resulting in the downstream phosphati-
dylinositol 3-kinase activity being decreased while the 
PI-3K activity is decreased, which will cause downstream 
tau protein phosphorylation [24]. The main kinase, gly-
cogen synthase kinase-3β, passes from a non-activated 
to an activated state. Thus, there will be hyperphospho-
rylation of tau protein leading to AD-like changes [25]. 
Therefore, we speculate that abnormal PI-3K pathway 
activation of glycogen synthase kinase-3β in an era of 
declining insulin caused tau protein phosphorylation to 
be increased in our model.
Analysis shows that the trajectory changes were differ-
ent over time. In diabetic rats at each time point, fluc-
tuations in Aβ42 and P-tau protein concentration in CSF 
appeared complementary, namely ‘shift’ changes over 
time. P-tau protein was on a gradually increasing trend 
when Aβ42 was decreased relative to controls, which is 








































Fig. 4 a Dynamic changes of Aβ42 in plasma of diabetic rats. In these figures, model rats (streptozotocin-treated group, n = 15) are compared with 
control rats (control group, n = 12). Mean ± standard deviation is shown. For intergroup comparisons: *P < 0.05, **P < 0.01; comparisons within 
diabetic group between time points: ##P < 0.01. b Brain tissue Aβ42 concentrations at day 75 (n = 10–12). For intergroup comparisons: *P < 0.05.
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found that in individual diabetic animals, lower Aβ42 in 
CSF at early times (day 15–day 30 time-points) appears 
to reduce the phenomenon of phosphorylated tau pro-
tein. The experiment also found that IL-6 expression at 
model day 60–day 75 was increased (P  <  0.01), plasma 
Aβ42 at model day 15 was decreased (P  <  0.01), and 
Aβ expression in rat brain tissue at model day 75 was 
increased (P  <  0.05). These results are consistent with 
previous reports [27].
Currently, intraperitoneal injection of STZ to induce 
learning and memory dysfunction in rodent models 
has academic recognition [28]. In agreement with this, 
the present study found that in the diabetes model at 
day 71, foraging time in the eight-arm maze was signifi-
cantly longer than in control rats. Our results suggest 
that changes in the measured biomarkers seem to appear 
earlier than learning and memory impairments since 
according to the work of others cognitive deficits do not 
appear earlier than 70 days after diabetes induction [29].
The above the trajectory analysis of biomarker change 
shows that reduced levels of Aβ42 in CSF is an early 
event, and that P-tau protein and IL-6 changes are later 
events. The above metabolic changes together determine 
the cognitive dysfunction in diabetic rats, and our study 
supports the hypothesis previously proposed, namely 
that changes in brain Aβ42, P-tau protein, IL-6, and 
ACh expression are the early events in diabetic memory 
impairment, and the latency period of the latter may 
provide an intervention time window for preventing 
cognitive impairment in DM. Moreover, deposition of 
brain Aβ42 predicts a cognitive-impairment pathologi-
cal process, and leads to synaptic dysfunction, culminat-
ing in cell loss and brain atrophy. Cognitive impairment 
induced by diabetes is characterized by a diversity of 
mechanisms, which dictates multi-target intervention 
strategies. At the same time, changes in the trajectory 
of different biomarkers at different stages of cognitive 
impairment due to the different mechanisms of injury 
determine drug selection. Another purpose of this exper-
iment was to study drug intervention strategies. Corre-
lation analysis showed that ACh, Aβ42, P-tau, and IL-6 
levels in the CSF of diabetic rats were not linearly related 
(P > 0.05), while further data analysis showed that ACh 
change and Aβ42, P-tau, and IL-6 were highly negatively 
correlated, suggesting that changes in ACh in diabetic 
rats were determined by the common factors in Aβ42, 
P-tau, and IL-6 variation. In the diabetes model at day 
0–day 30, P-tau and IL-6 are not a significant source of 
variation, Aβ42 and ACh being the main factors chang-
ing. Aβ42 content in CSF was reduced, reaching a mini-
mum at day 30. In light of the above analysis, the results 
suggest that in terms of choice of drug intervention 
strategies, blood glucose should be controlled to rectify 
the early Aβ42 protein deposition, etc., due to the dou-
ble impact of glycosylation and insulin elevation, thus 
preventing possible cognitive damage. This study also 
found increases in P-tau and IL-6 protein in CSF in the 
diabetic model at day 60–day 75, but by this time Aβ42 
changes had stabilized. At this stage, it is believed that 
the main factors causing cognitive impairment effects are 
decreased ACh content and increased P-tau protein and 
IL-6 in CSF. Based on the above considerations, targeted 
intervention therapy with drugs to ameliorate insulin 
resistance and combat inflammation should be consid-
ered the best choice for this latter stage.
This study has some limitations, such as the lack of 
effective mathematical methods for studying the quan-
titative characteristics of the biomarkers. In future, we 
intend to use mathematical methods to reveal the quan-
titative relationships among the various markers and 
the dependence of each marker on time. Moreover, the 
study did not use a model appropriate to proving the 
effectiveness of specific drug intervention strategies. In 
subsequent experiments, these problems will be further 
addressed.
Conclusions
We found that the trajectories of Aβ42, P-tau, IL-6, and 
ACh levels in CSF were different in dissimilar stages 
of diabetes-accelerated memory dysfunction in rats. 
Results from our longitudinal research model suggest 
that changes in the measured biomarkers appear before 
Table 2 Correlation analysis of Aβ42 in blood and cerebro-
spinal fluid in diabetic rats
The Pearson correlation test was used. P < 0.05 (*) was adopted as the 
significance level for all tests. P > 0.05 (NS) was not considered significant. Results 
are shown for day 0 to day 75 in diabetic model rats (n = 15).
Time point Pearson correlation P value
Day 0 0.327NS 0.295
Day 15 −0.647NS 0.174
Day 30 −0.623NS 0.283
Day 45 0.604NS 0.140
Day 75 −0.693NS 0.256
Table 3 Learning and  memory capacity in  diabetic rats 
at day 71—eight-arm maze test
A rat diabetes model (streptozotocin-treated group, n = 15) is compared with 
control (n = 10). Means ± standard deviations are shown. For intergroup 
comparisons: *P < 0.05, **P < 0.01.
Group n Foraging time (s) Number of reference 
errors
Control 10 366.5 ± 64.8 2.78 ± 0.33
Model 15 505.5 ± 53.3* 5.40 ± 0.85**
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learning and memory impairments do. In the diabetes 
model group, Aβ42 and ACh changed obviously from 
day 0 to day 45, after which P-tau and IL-6 varied signifi-
cantly from day 45 to day 75. In our diabetes model, Aβ42 
in CSF may be correlated with blood glucose in rats from 
day 0 to day 45, after which it correlates strongly with 
insulin. The reduced ACh levels observed possibly corre-
lated with the factors common to changes in Aβ42, P-tau, 
and IL-6.
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